Phase II
Eli Lilly announced that it is pausing its clinical trial of a combination antibody against COVID-19 over safety concerns. Typically, this would be because a patient or volunteer showed a serious side effect or became sick, but the company did not clarify what the reason for the pause is.
Gossamer Bio announced today that its two studies examining GB001 – the Phase IIb LEDA trial in eosinophilic asthma and Phase II TITAN trial in chronic rhinosinusitis – failed to meet their primary endpoints.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
It was a moderately busy week for clinical trial news. Here’s a look.
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).
New long-term safety and efficacy data highlights the medication’s capabilities in allowing patients to maintain fewer migraine days over a period of five years.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
The trial was initially placed on hold in November 2019 due to safety concerns.
PRESS RELEASES